Cancer Research AACR Membership EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrara, F. F.
Right arrow Articles by Nervi, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrara, F. F.
Right arrow Articles by Nervi, C.
[Cancer Research 61, 2-7, January 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Histone Deacetylase-targeted Treatment Restores Retinoic Acid Signaling and Differentiation in Acute Myeloid Leukemia1

Fabiana F. Ferrara2, Francesco Fazi2, Andrea Bianchini, Fabrizio Padula, Vania Gelmetti, Saverio Minucci, Marco Mancini, Pier Giuseppe Pelicci, Francesco Lo Coco and Clara Nervi3

Departments of Histology and Medical Embryology [F. F. F., F. F., A. B., F. P., C. N.] and Cellular Biotechnology and Hematology [M. M., F. L. C.], University of Rome "La Sapienza," 00161 Rome; Institute of Internal Medicine and Oncological Sciences, 06100 Perugia [V. G.]; European Institute of Oncology, Department of Experimental Oncology, 20141 Milan [S. M., P. G. P.], Italy

Histone deacetylase (HDAC)-dependent transcriptional repression of the retinoic acid (RA)-signaling pathway underlies the differentiation block of acute promyelocytic leukemia. RA treatment relieves transcriptional repression and triggers differentiation of acute promyelocytic leukemia blasts, leading to disease remission. We report that transcriptional repression of RA signaling is a common mechanism in acute myeloid leukemias (AMLs). HDAC inhibitors restored RA-dependent transcriptional activation and triggered terminal differentiation of primary blasts from 23 AML patients. Accordingly, we show that AML1/ETO, the commonest AML-associated fusion protein, is an HDAC-dependent repressor of RA signaling. These findings relate alteration of the RA pathway to myeloid leukemogenesis and underscore the potential of transcriptional/differentiation therapy in AML.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Bots and R. W. Johnstone
Rational Combinations Using HDAC Inhibitors
Clin. Cancer Res., June 15, 2009; 15(12): 3970 - 3977.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. M. Odenike, S. Alkan, D. Sher, J. E. Godwin, D. Huo, S. J. Brandt, M. Green, J. Xie, Y. Zhang, D. H. Vesole, et al.
Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia
Clin. Cancer Res., November 1, 2008; 14(21): 7095 - 7101.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. K. Hahn, K. N. Ross, I. M. Warrington, R. Mazitschek, C. M. Kanegai, R. D. Wright, A. L. Kung, T. R. Golub, and K. Stegmaier
Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation
PNAS, July 15, 2008; 105(28): 9751 - 9756.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
F. L. Martin
Epigenomics and disease, 10th anniversary winter meeting of the UK Molecular Epidemiology Group (MEG), The Royal Statistical Society, London, UK, 8th December 2006
Mutagenesis, November 1, 2007; 22(6): 425 - 427.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
T. Siitonen, T. Timonen, E. Juvonen, V. Terava, A. Kutila, T. Honkanen, M. Mikkola, H. Hallman, M. Kauppila, P. Nylanden, et al.
Valproic acid combined with 13-cis retinoic acid and 1,25-dihydroxyvitamin D3 in the treatment of patients with myelodysplastic syndromes
Haematologica, August 1, 2007; 92(8): 1119 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Fazi, G. Zardo, V. Gelmetti, L. Travaglini, A. Ciolfi, L. Di Croce, A. Rosa, I. Bozzoni, F. Grignani, F. Lo-Coco, et al.
Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia
Blood, May 15, 2007; 109(10): 4432 - 4440.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. Bug, K. Schwarz, C. Schoch, M. Kampfmann, R. Henschler, D. Hoelzer, O. G. Ottmann, and M. Ruthardt
Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia
Haematologica, April 1, 2007; 92(4): 542 - 545.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al.
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
Blood, April 1, 2007; 109(7): 2781 - 2790.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
X. Zheng, A. Seshire, B. Ruster, G. Bug, T. Beissert, E. Puccetti, D. Hoelzer, R. Henschler, and M. Ruthardt
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RAR{alpha}-positive leukemic stem cells
Haematologica, March 1, 2007; 92(3): 323 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Ohnuma-Ishikawa, T. Morio, T. Yamada, Y. Sugawara, M. Ono, M. Nagasawa, A. Yasuda, C. Morimoto, K. Ohnuma, N. H. Dang, et al.
Knockdown of XAB2 Enhances All-Trans Retinoic Acid-Induced Cellular Differentiation in All-Trans Retinoic Acid-Sensitive and -Resistant Cancer Cells
Cancer Res., February 1, 2007; 67(3): 1019 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Cimino, F. Lo-Coco, S. Fenu, L. Travaglini, E. Finolezzi, M. Mancini, M. Nanni, A. Careddu, F. Fazi, F. Padula, et al.
Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia.
Cancer Res., September 1, 2006; 66(17): 8903 - 8911.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Fouladi, W. L. Furman, T. Chin, B. B. Freeman III, L. Dudkin, C. F. Stewart, M. D. Krailo, R. Speights, A. M. Ingle, P. J. Houghton, et al.
Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report
J. Clin. Oncol., August 1, 2006; 24(22): 3678 - 3685.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
T. Thomas, L. M. Corcoran, R. Gugasyan, M. P. Dixon, T. Brodnicki, S. L. Nutt, D. Metcalf, and A. K. Voss
Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells.
Genes & Dev., May 1, 2006; 20(9): 1175 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
N. K. Mukhopadhyay, E. Weisberg, D. Gilchrist, R. Bueno, D. J. Sugarbaker, and M. T. Jaklitsch
Effectiveness of Trichostatin A as a Potential Candidate for Anticancer Therapy in Non-Small-Cell Lung Cancer
Ann. Thorac. Surg., March 1, 2006; 81(3): 1034 - 1042.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Xu, F. Guidez, A. Glasow, D. Chung, K. Petrie, K. Stegmaier, K.-K. Wang, J. Zhang, Y. Jing, A. Zelent, et al.
Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor {alpha} and Enhancing Changes in all-trans-Retinoic Acid-Regulated Gene Expression
Cancer Res., September 1, 2005; 65(17): 7856 - 7865.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Puccetti, X. Zheng, D. Brambilla, A. Seshire, T. Beissert, S. Boehrer, H. Nurnberger, D. Hoelzer, O. G. Ottmann, C. Nervi, et al.
The Integrity of the Charged Pocket in the BTB/POZ Domain Is Essential for the Phenotype Induced by the Leukemia-Associated t(11;17) Fusion Protein PLZF/RAR{alpha}
Cancer Res., July 15, 2005; 65(14): 6080 - 6088.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. N. Bhalla
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. De Felice, C. Tatarelli, M. G. Mascolo, C. Gregorj, F. Agostini, R. Fiorini, V. Gelmetti, S. Pascale, F. Padula, M. T. Petrucci, et al.
Histone Deacetylase Inhibitor Valproic Acid Enhances the Cytokine-Induced Expansion of Human Hematopoietic Stem Cells
Cancer Res., February 15, 2005; 65(4): 1505 - 1513.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al.
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
Blood, February 1, 2005; 105(3): 959 - 967.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Glasow, N. Prodromou, K. Xu, M. von Lindern, and A. Zelent
Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways
Blood, January 1, 2005; 105(1): 341 - 349.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Witcher, H. Y. Shiu, Q. Guo, and W. H. Miller Jr
Combination of retinoic acid and tumor necrosis factor overcomes the maturation block in a variety of retinoic acid-resistant acute promyelocytic leukemia cells
Blood, November 15, 2004; 104(10): 3335 - 3342.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Shimizu, M. Suzui, A. Deguchi, J. T. E. Lim, D. Xiao, J. H. Hayes, K. P. Papadopoulos, and I. B. Weinstein
Synergistic Effects of Acyclic Retinoid and OSI-461 on Growth Inhibition and Gene Expression in Human Hepatoma Cells
Clin. Cancer Res., October 1, 2004; 10(19): 6710 - 6721.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Kuendgen, C. Strupp, M. Aivado, A. Bernhardt, B. Hildebrandt, R. Haas, U. Germing, and N. Gattermann
Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid
Blood, September 1, 2004; 104(5): 1266 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
C. Muller-Tidow, B. Steffen, T. Cauvet, L. Tickenbrock, P. Ji, S. Diederichs, B. Sargin, G. Kohler, M. Stelljes, E. Puccetti, et al.
Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells
Mol. Cell. Biol., April 1, 2004; 24(7): 2890 - 2904.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Atadja, L. Gao, P. Kwon, N. Trogani, H. Walker, M. Hsu, L. Yeleswarapu, N. Chandramouli, L. Perez, R. Versace, et al.
Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824
Cancer Res., January 15, 2004; 64(2): 689 - 695.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Gozzini, E. Rovida, P. Dello Sbarba, S. Galimbert, and V. Santini
Butyrates, as a Single Drug, Induce Histone Acetylation and Granulocytic Maturation: Possible Selectivity on Core Binding Factor-Acute Myeloid Leukemia Blasts
Cancer Res., December 15, 2003; 63(24): 8955 - 8961.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. Kopelovich, J. A. Crowell, and J. R. Fay
The Epigenome as a Target for Cancer Chemoprevention
J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Lu, I. Goldenberg, L. Bei, J. Andrejic, and E. A. Eklund
HoxA10 Represses Gene Transcription in Undifferentiated Myeloid Cells by Interaction with Histone Deacetylase 2
J. Biol. Chem., November 28, 2003; 278(48): 47792 - 47802.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
K. K. Mann, A. Rephaeli, A. L. Colosimo, Z. Diaz, A. Nudelman, I. Levovich, Y. Jing, S. Waxman, and W. H. Miller Jr.
A Retinoid/Butyric Acid Prodrug Overcomes Retinoic Acid Resistance in Leukemias by Induction of Apoptosis
Mol. Cancer Res., October 1, 2003; 1(12): 903 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
W. Shi, A. Hoeflich, H. Flaswinkel, M. Stojkovic, E. Wolf, and V. Zakhartchenko
Induction of a Senescent-Like Phenotype Does Not Confer the Ability of Bovine Immortal Cells to Support the Development of Nuclear Transfer Embryos
Biol Reprod, July 1, 2003; 69(1): 301 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Puccetti, D. Obradovic, T. Beissert, A. Bianchini, B. Washburn, F. Chiaradonna, S. Boehrer, D. Hoelzer, O. G. Ottmann, P. G. Pelicci, et al.
AML-associated Translocation Products Block Vitamin D3-induced Differentiation by Sequestering the Vitamin D3 Receptor
Cancer Res., December 1, 2002; 62(23): 7050 - 7058.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
M.-C. Guillemin, E. Raffoux, D. Vitoux, S. Kogan, H. Soilihi, V. Lallemand-Breitenbach, J. Zhu, A. Janin, M.-T. Daniel, B. Gourmel, et al.
In Vivo Activation of cAMP Signaling Induces Growth Arrest and Differentiation in Acute Promyelocytic Leukemia
J. Exp. Med., November 18, 2002; 196(10): 1373 - 1380.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Pisano, P. Kollar, M. Gianni, Y. Kalac, V. Giordano, F. F. Ferrara, R. Tancredi, A. Devoto, A. Rinaldi, A. Rambaldi, et al.
Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells
Blood, November 15, 2002; 100(10): 3719 - 3730.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Jaboin, J. Wild, H. Hamidi, C. Khanna, C. J. Kim, R. Robey, S. E. Bates, and C. J. Thiele
MS-27-275, an Inhibitor of Histone Deacetylase, Has Marked in Vitro and in Vivo Antitumor Activity against Pediatric Solid Tumors
Cancer Res., November 1, 2002; 62(21): 6108 - 6115.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. A. Strait, B. Dabbas, E. H. Hammond, C. T. Warnick, S. J. Ilstrup, and C. D. Ford
Cell Cycle Blockade and Differentiation of Ovarian Cancer Cells by the Histone Deacetylase Inhibitor Trichostatin A Are Associated with Changes in p21, Rb, and Id Proteins
Mol. Cancer Ther., November 1, 2002; 1(13): 1181 - 1190.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Cote, A. Rosenauer, A. Bianchini, K. Seiter, J. Vandewiele, C. Nervi, and W. H. Miller Jr
Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells
Blood, September 18, 2002; 100(7): 2586 - 2596.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. C. Petti, F. Fazi, M. Gentile, D. Diverio, P. De Fabritiis, M. S. De Propris, R. Fiorini, M. A. A. Spiriti, F. Padula, P. G. Pelicci, et al.
Complete remission through blast cell differentiation in PLZF/RARalpha -positive acute promyelocytic leukemia: in vitro and in vivo studies
Blood, July 18, 2002; 100(3): 1065 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
A. D. Weston, R. A.S. Chandraratna, J. Torchia, and T. M. Underhill
Requirement for RAR-mediated gene repression in skeletal progenitor differentiation
J. Cell Biol., July 8, 2002; 158(1): 39 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
B. M. Scicchitano, L. Spath, A. Musaro, M. Molinaro, S. Adamo, and C. Nervi
AVP Induces Myogenesis through the Transcriptional Activation of the Myocyte Enhancer Factor 2
Mol. Endocrinol., June 1, 2002; 16(6): 1407 - 1416.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. B. Sporn
Hobson's Choice and the Need for Combinations of New Agents for the Prevention and Treatment of Breast Cancer
J Natl Cancer Inst, February 20, 2002; 94(4): 242 - 243.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
V. Vivat-Hannah, D. You, C. Rizzo, J.-P. Daris, P. Lapointe, F. C. Zusi, A. Marinier, M. V. Lorenzi, and M. M. Gottardis
Synergistic Cytotoxicity Exhibited by Combination Treatment of Selective Retinoid Ligands with Taxol (Paclitaxel)
Cancer Res., December 1, 2001; 61(24): 8703 - 8711.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Zhu, C. M. Heyworth, A. Glasow, Q.-H. Huang, K. Petrie, M. Lanotte, G. Benoit, R. Gallagher, S. Waxman, T. Enver, et al.
Lineage restriction of the RAR{alpha} gene expression in myeloid differentiation
Blood, October 15, 2001; 98(8): 2563 - 2567.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. M. Amann, J. Nip, D. K. Strom, B. Lutterbach, H. Harada, N. Lenny, J. R. Downing, S. Meyers, and S. W. Hiebert
ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through Its Oligomerization Domain
Mol. Cell. Biol., October 1, 2001; 21(19): 6470 - 6483.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Smith and B. Anderson
Where to Next with Retinoids for Cancer Therapy?
Clin. Cancer Res., October 1, 2001; 7(10): 2955 - 2957.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. S. J. Elenitoba-Johnson
Complex Regulation of Telomerase Activity : Implications for Cancer Therapy
Am. J. Pathol., August 1, 2001; 159(2): 405 - 410.
[Full Text]

Home page
 Cancer Res.Home page
C. Nervi, U. Borello, F. Fazi, V. Buffa, P. G. Pelicci, and G. Cossu
Inhibition of Histone Deacetylase Activity by Trichostatin A Modulates Gene Expression during Mouse Embryogenesis without Apparent Toxicity
Cancer Res., February 1, 2001; 61(4): 1247 - 1249.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.